Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ruthenium red is a polycationic inorganic dye, chemically a complex of ammoniated ruthenium oxychloride, most commonly used as a histological and cytological stain for visualizing mucopolysaccharides and aldehyde-fixed biological samples[3][4][5]. It is also widely used in research as a pharmacological tool; it is a nonselective inhibitor of multiple calcium-permeable ion channels, including ryanodine receptors, L-type voltage-gated calcium channels, and mitochondrial calcium uniporters[2][3][5][7][8][9]. Ruthenium red inhibits release and uptake of calcium in mitochondria and the sarcoplasmic reticulum, and also blocks several transient receptor potential (TRP) channels, among other ion channels[3][9]. Due to its broad calcium channel blocking activity, it is also used experimentally to modulate intracellular calcium dynamics. Ruthenium red is mainly utilized for laboratory and research purposes—there is no evidence for therapeutic medical use or pharmaceutical approvals in humans.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ruthenium red.